Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 3 | Cancer Cell International

Figure 3

From: Anti-tumor effect of ribavirin in combination with interferon-α on renal cell carcinoma cell lines in vitro

Figure 3

Combined treatment with ribavirin and IFN-α affected the RCC cell cycle. (A) Combination of 500 IU/ml of IFN-α and 500 μM ribavirin blocked the G2/M phase cell cycle transition of 786–0 cells, in comparison with untreated control 786–0 cells. The percentage of 786–0 cells in the G0/G1 phase increased significantly to 58.32% but the percentage of cells in the G2/M phase decreased to 13.95%. (B) Quantitative analysis of the cell cycle distribution of 786–0 cells treated with ribavirin alone, IFN-α alone, or a combination of ribavirin and IFN-α (* < 0.05 versus control group).

Back to article page